Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | SCN9A | Q15858 | 8/20 | 0.34 |
| ▸ | MEN1 | O00255 | 4/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.32 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.32 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14921743 | 0.92 | SMN1; SMN2 (0.39) | NPC1RAB9ASMN1; SMN2KDM4EMEN1 | |
| SCHEMBL16187171 | 0.92 | MEN1 (0.33) | NPC1RAB9ASMN1; SMN2SCN9AMEN1 | |
| SCHEMBL1095453 | 0.90 | SMN1; SMN2 (0.37) | NPC1RAB9ASMN1; SMN2KDM4ESCN9A | |
| SCHEMBL319968 | 0.88 | NPC1 (0.35) | NPC1RAB9ASMN1; SMN2KDM4EHTR2A | |
| SCHEMBL320928 | 0.88 | SOS1 (0.38) | NPC1RAB9ASMN1; SMN2KDM4EHTR2A | |
| SCHEMBL18352655 | 0.88 | MEN1 (0.40) | SCN9AMEN1KMT2ATSHR | |
| SCHEMBL16223569 | 0.87 | NPC1 (0.34) | NPC1RAB9ASMN1; SMN2KDM4ESCN9A | |
| SCHEMBL16223775 | 0.87 | MEN1 (0.34) | NPC1RAB9ASMN1; SMN2KDM4ESCN9A | |
| SCHEMBL16223620 | 0.86 | SMN1; SMN2 (0.33) | NPC1RAB9ASMN1; SMN2KDM4ESCN9A | |
| SCHEMBL16223538 | 0.86 | NPC1 (0.33) | NPC1RAB9ASMN1; SMN2KDM4ESCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3144300-B1 | METHODS OF PRODUCING 4-CYCLOALKYLOXYBENZENESULFONAMIDES | DAIICHI SANKYO CO LTD (JP) | 2017-12-20 | — | — | EP | disclosed |
| US-9845313-B2 | Cycloalkane derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2017-12-19 | — | — | US | disclosed |
| US-20170275275-A1 | BENZENESULFONAMIDES USEFUL AS SODIUM CHANNEL INHIBITORS | PFIZER (US) | 2017-09-28 | — | — | US | disclosed |
| EP-3148992-A1 | BENZENESULFONAMIDES USEFUL AS SODIUM CHANNEL INHIBITORS | Pfizer Inc. (US) | 2017-04-05 | — | — | EP | disclosed |
| EP-3144300-A1 | METHODS OF PRODUCING 4-CYCLOALKYLOXYBENZENESULFONAMIDES | Daiichi Sankyo Company, Limited (JP) | 2017-03-22 | — | — | EP | disclosed |
| US-20170001984-A1 | CYCLOALKANE DERIVATIVES | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2017-01-05 | — | — | US | disclosed |
| US-9493448-B2 | Cycloalkane derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2016-11-15 | — | — | US | disclosed |
| EP-2813491-B1 | CYCLOALKANE DERIVATIVE | DAIICHI SANKYO CO LTD (JP) | 2016-11-02 | — | — | EP | disclosed |
| WO-2015181797-A1 | BENZENESULFONAMIDES USEFUL AS SODIUM CHANNEL INHIBITORS | PFIZER INC. (US) | 2015-12-03 | — | — | WO | disclosed |
| US-9145407-B2 | Sulfonamide compounds | PFIZER LIMITED (GB) | 2015-09-29 | — | — | US | disclosed |
| WO-2012004714-A2 | CHEMICAL COMPOUNDS | PFIZER LIMITED (GB) | 2012-01-12 | — | — | WO | disclosed |
| WO-2012004714-A2 | CHEMICAL COMPOUNDS | PFIZER LIMITED (GB) | 2012-01-12 | — | — | WO | disclosed |
| WO-2012004706-A2 | CHEMICAL COMPOUNDS | PFIZER LIMITED (GB) | 2012-01-12 | — | — | WO | disclosed |
| EP-2385938-A1 | SULFONAMIDE DERIVATIVES | Pfizer Limited (GB) | 2011-11-16 | — | — | EP | disclosed |
| US-8040476-B2 | Display device and method of producing the same | MITSUBISHI ELECTRIC CORPORATION (JP) | 2011-10-18 | — | — | US | disclosed |
| US-20100197655-A1 | SULFONAMIDE DERIVATIVES | Pfizer Limited Icagen, Inc. | 2010-08-05 | — | — | US | disclosed |
| US-20100197655-A1 | SULFONAMIDE DERIVATIVES | Pfizer Limited Icagen, Inc. | 2010-08-05 | — | — | US | disclosed |
| US-20100197655-A1 | SULFONAMIDE DERIVATIVES | Pfizer Limited Icagen, Inc. | 2010-08-05 | — | — | US | disclosed |
| WO-2010079443-A1 | SULFONAMIDE DERIVATIVES | PFIZER LIMITED (GB) | 2010-07-15 | — | — | WO | disclosed |
| WO-2010079443-A1 | SULFONAMIDE DERIVATIVES | PFIZER LIMITED (GB) | 2010-07-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197655-A1 | SULFONAMIDE DERIVATIVES | SULT2A1, SULT1A1, TPST2 | NPC1 3772/4885RAB9A 4083/4885SMN1; SMN2 86/4885 |
| US-20170001984-A1 | CYCLOALKANE DERIVATIVES | TRPV1, TRPA1, SCNN1A | NPC1 329/4885RAB9A 2550/4885SMN1; SMN2 1785/4885 |
| US-20170275275-A1 | BENZENESULFONAMIDES USEFUL AS SODIUM CHANNEL INHIBITORS | SCN7A, SCN1A, SCN2B | NPC1 2877/4885RAB9A 1169/4885SMN1; SMN2 322/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.